SCHEMBL7070930

SCHEMBL7070930

COp1oc2c(C(C)(C)C)cc(C(C)(C)C)cc2c2cc(C(C)(C)C)cc(C(C)(C)C)c2o1

nearest known ligand 0.30

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.30
TP53 P04637 1/20 0.30
CYP3A4 P08684 1/20 0.30
HPGD P15428 1/20 0.30
ALOX15 P16050 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9004214 0.88 CA2 (0.30)
SCHEMBL13246061 0.83 CYP1A2 (0.31) CYP3A4
SCHEMBL7029199 0.82
SCHEMBL6906715 0.81 CA1 (0.46) LMNATP53CYP3A4HPGDALOX15
SCHEMBL29851517 0.81 CA1 (0.46) LMNATP53CYP3A4HPGDALOX15
SCHEMBL13290054 0.81 RARG (0.31)
SCHEMBL22996234 0.81
SCHEMBL10305207 0.80 GABRA1 (0.31)
SCHEMBL86121 0.80 HTR1D (0.37)
SCHEMBL31194410 0.80 HTR1D (0.37)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0885911-B1 Two-component catalyst for ring-opening metathesis polymerization CIBA SC HOLDING AG (CH) 2003-06-18 EP claimed
US-5998326-A Two-component catalyst for ROMP CIBA SPECIALTY CHEMICALS CORP. (US) 1999-12-07 US claimed
EP-0885911-A1 Two-component catalyst for ring-opening metathesis polymerization Ciba SC Holding AG (CH) 1998-12-23 EP claimed
WO-2019053187-A1 ADDITIVE MIXTURE BASF SE (DE) 2019-03-21 WO disclosed
WO-2019007935-A1 A POLYETHYLENE PIPE BASF SE (DE) 2019-01-10 WO disclosed
US-9039946-B2 Reversibly thermochromic compositions BASF SE (DE) 2015-05-26 US disclosed
EP-1888686-B1 SCRATCH RESISTANT POLYOLEFINS BASF SE (DE) 2013-01-23 EP disclosed
US-20100036083-A1 Process For The Preparation Of Polyamides In The Presence of a Phosphonate CIBA SPECIALTY CHEMICALS CORPORATION (US) 2010-02-11 US disclosed
US-20090302284-A1 Reversibly Thermochromic Compositions CIBA CORPORATION 2009-12-10 US disclosed
EP-1008580-B2 Process for preparing aldehydes and alcohols MITSUBISHI CHEM CORP (JP) 2008-10-29 EP disclosed
EP-1704026-B1 METHOD OF TREATING RAZOR BLADE CUTTING EDGES GILLETTE CO (US) 2008-05-21 EP disclosed
US-20070055047-A1 Molecular weight increase and modification of polycondensates CIBA SPECIALTY CHEMICALS CORP. 2007-03-08 US disclosed
EP-0885911-B1 Two-component catalyst for ring-opening metathesis polymerization CIBA SC HOLDING AG (CH) 2003-06-18 EP disclosed
US-6204347-B1 CONSIST OF A MIXTURE OF STRAINED CYCLOOLEFIN AND A RUTHENIUM COMPOUND, AND A MIXTURE OF STRAINED CYCLOOLEFIN AND A TERTIARY PHOSPHINE CONTAINING ATLEAST ONE SECONDARY ALKYL REDICAL OR CYCLOALKYL REDICAL TO PHOSPHORUS ATOM CIBA SPECIALTY CHEMICALS CORPORATION 2001-03-20 US disclosed
US-5998326-A Two-component catalyst for ROMP CIBA SPECIALTY CHEMICALS CORP. (US) 1999-12-07 US disclosed
EP-0885911-A1 Two-component catalyst for ring-opening metathesis polymerization Ciba SC Holding AG (CH) 1998-12-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090302284-A1 Reversibly Thermochromic Compositions DHCR7, NES, DUT LMNA 1554/4885TP53 505/4885CYP3A4 998/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.